9-valent HPV vaccine
Sponsors
Ando Naokatsu, Yale University, Universitaire Ziekenhuizen KU Leuven, Augusta University, Shanghai Bovax Biotechnology Co., Ltd.
Conditions
AISCIN 3CIN1CIN2CIN3Cervical CancerCervical DysplasiaCervical Intraepithelial Neoplasia
Phase 2
Phase 3
Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients
CompletedNCT03525210
Start: 2018-04-04End: 2020-07-15Updated: 2020-12-11
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
CompletedNCT04425291
Start: 2020-05-28End: 2021-09-06Updated: 2022-02-25
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
RecruitingNCT04895020
Start: 2021-05-28End: 2026-05-31Target: 1200Updated: 2024-04-17
Phase 4
9-valent HPV Vaccine in Postpartum Women
NCT04311528
Start: 2020-04-01End: 2021-12-31Target: 100Updated: 2020-03-17
Immunogenicity of 9-valent HPV Vaccine
RecruitingNCT05439083
Start: 2023-03-07End: 2025-03-01Target: 120Updated: 2024-03-08
A Randomized Clinical Trial to Compare the Efficacy and Immunogenicity of Single-Dose versus Two-Dose HPV Vaccination in Men
RecruitingJPRN-jRCTs031240746
Start: 2025-04-15Target: 220Updated: 2026-06-29
Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years
Active, not recruitingNCT07281677
Start: 2025-12-20End: 2029-11-13Updated: 2026-06-11